The landscape of the Medicare Advantage (MA) program has undergone a dramatic transformation with the release of the 2027 Star Ratings by the Centers for Medicare & Medicaid Services (CMS). As the privatized arm of the federal Medicare program faces intense scrutiny over profitability and service quality, the latest data reveals a tale of two extremes: a remarkable comeback for industry giant Humana and a bruising setback for smaller, growth-focused players like Alignment Healthcare.
For the millions of seniors relying on these private plans, these ratings are more than just internal metrics—they are the primary indicators of quality, service, and, ultimately, the sustainability of the benefits they receive. With the industry facing a third consecutive year of tightening margins and benefit reductions, the 2027 ratings have become the definitive battleground for financial stability in the health insurance sector.
The 2027 Performance Landscape: Key Facts and Findings
The CMS Star Ratings, which utilize a scale of one to five, are the primary mechanism through which the federal government evaluates the performance of private Medicare plans. These scores are not merely administrative; they are directly linked to “Quality Bonus Payments” (QBPs) and rebate dollars that plans use to offer supplemental benefits—such as dental, vision, hearing, and fitness programs—that traditional Medicare does not cover.
In 2027, the industry experienced a general cooling in performance. The average enrollment-weighted star rating dipped to 3.99, down from 4.01 in the previous year. Furthermore, the percentage of MA plans with drug coverage earning 4 stars or higher fell to 37%, a significant decline from 44% in 2026. This downward trend is widely attributed to more rigorous methodology adjustments by the CMS, which updated its weighting system and raised performance thresholds, effectively raising the bar for insurers at a time when medical loss ratios are already under extreme pressure.
A Tale of Two Insurers: Humana’s Resurrection and Alignment’s Struggle
The most striking narrative emerging from the 2027 data is the monumental recovery of Humana. As the second-largest insurer in the Medicare Advantage space, Humana had spent the previous two years in a state of crisis. Following a catastrophic decline in ratings—where the percentage of its members in 4-star-plus plans plummeted from 94% in 2024 to a dismal 20% in 2026—the company faced a precarious financial future.
In a move that surprised many analysts, Humana has effectively reversed that trend. The percentage of its members in high-performing 4-star-plus plans has skyrocketed to 93% for the 2027 cycle. This turnaround is not just a PR victory; it is a massive financial stabilizer. Industry analysts at TD Cowen, led by Ryan Langston, estimate that this recovery could yield Humana an additional $3 billion or more in revenue for 2028, the year in which the 2027 performance data begins to influence payment structures. Following the announcement, Humana’s stock surged nearly 13% in post-market trading, signaling high investor confidence in the company’s operational remediation.
Conversely, the news for Alignment Healthcare was starkly different. One of the industry’s most prominent mid-sized players, Alignment saw its largest contract fall below the critical 4-star threshold. The impact is profound: whereas 98% of its members were previously in 4-star-plus plans, that figure is projected to drop to just 25% for 2027. This represents a major setback for the company, with analysts estimating a potential revenue loss of over $170 million in 2028. Following the release of the data, Alignment’s shares fell by more than 20%, highlighting the market’s sensitivity to the direct correlation between Star Ratings and long-term solvency.
Chronology: A Multi-Year Battle over Methodology
To understand the volatility of the 2027 ratings, one must look at the recent history of the CMS’s relationship with private insurers. The industry has been locked in a multi-year conflict with the federal government regarding how these ratings are calculated.
- 2025-2026: A period of significant volatility. Humana and other major players saw their ratings slip as the CMS began implementing stricter quality measures. During this time, smaller players like Clover Health initiated litigation against the CMS, arguing that the agency’s methodology was fundamentally flawed and inconsistent.
- Late 2025: A federal judge sided with Clover Health, ruling that the CMS’s methodology for specific star measures was unlawful. This forced the agency to recalculate 2026 ratings for several carriers, providing a temporary reprieve for some insurers that would have otherwise seen even lower scores.
- 2026-2027: The CMS responded to the legal and administrative pressure by recalibrating its scoring system for the 2027 cycle. They introduced new measures and adjusted the weighting of existing ones, a move that experts warned would make achieving 4-star status significantly more difficult.
- October 2024: The current ratings are released, confirming that the new methodology successfully curtailed the number of high-performing plans, with only 15 contracts achieving the elusive 5-star rating, down from 22 in the previous cycle.
Official Responses and Strategic Defiance
The reaction to the 2027 ratings has been characterized by both cautious optimism from winners and aggressive legal posturing from those who fell short.
For Humana, the results serve as validation of a multi-year strategic pivot. J.P. Morgan analyst Lisa Gill noted that the outcome was a "clear win," suggesting that the company’s internal operational changes—likely focused on improved patient care coordination and documentation accuracy—have finally borne fruit.
Alignment Healthcare, however, has signaled its intention to fight back. In a formal statement, Dawn Maroney, president of Alignment’s health plan, expressed strong disagreement with the CMS’s assessment. "We intend to pursue all available administrative remedies and to litigate the measures and methodologies we believe warrant review," Maroney stated. Alignment is effectively questioning the statistical validity of the CMS’s new scoring, suggesting that the metrics do not capture the true value of their care delivery model.
Clover Health, having successfully navigated the legal system in previous years, celebrated its retention of a 5-star rating for one of its contracts. Jamie Reynoso, CEO of Clover’s MA business, emphasized in a press release that the rating is a testament to the company’s commitment to "benefits, affordability, and wide choice of providers."
The Broader Implications for Seniors and the Healthcare System
While the battle over stars is often framed as a corporate finance story, the human impact on the American senior population cannot be overstated. The Medicare Advantage program is currently undergoing its most difficult period in recent memory.
1. Benefit Erosion and Plan Terminations
The downward pressure on Star Ratings is compounding the challenges caused by rising medical costs. With lower bonus payments, many insurers are finding it mathematically impossible to maintain the generous supplemental benefits—such as dental and gym memberships—that defined the MA market during the growth years of 2020–2023. As a result, 2027 is expected to see a continuation of the "plan culling" trend, where insurers exit counties or terminate entire products to protect their bottom lines. More than 3 million seniors were impacted by plan changes in the last cycle alone.
2. The Potential for Increased Out-of-Pocket Costs
For major carriers like UnitedHealth, CVS (Aetna), and others that saw a dip in their high-star membership, the strategy for 2028 is becoming clear: focus on margin preservation. Experts warn that this may manifest as increased cost-sharing for enrollees, more restrictive prior authorization requirements, and narrower physician networks. As these large insurers control the lion’s share of the market, their internal cost-cutting measures effectively dictate the quality of care for millions of Americans.
3. A Tumultuous Enrollment Period
As Medicare open enrollment begins on October 15, the message from advocates is clear: caution is paramount. The volatility in the 2027 ratings suggests that the plan a senior had this year may not be the same in terms of coverage or affordability next year. Patient advocacy groups are urging seniors to perform a granular review of their plan’s current network and benefit structures rather than relying on historical reputation or previous star ratings.
Conclusion: A New Era of Medicare Advantage
The 2027 Star Ratings represent a definitive end to the era of easy growth in the Medicare Advantage sector. The divergence between Humana’s recovery and the struggles of other major players highlights the extreme operational complexity required to navigate the current regulatory environment.
For investors, the data provides a clear roadmap of which companies have successfully adapted to the CMS’s new, more rigorous quality standards. For the healthcare system at large, the ratings serve as a warning sign: as the federal government tightens the purse strings, the "bonus-funded" benefits that have made Medicare Advantage so popular are increasingly at risk. As the industry moves toward the 2028 plan year, the ability of insurers to deliver high-quality care while maintaining financial sustainability will be the ultimate measure of their survival in a tightening market.
